Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Substance Withdrawal Syndrome 1Prostatic Neoplasms 1Overweight 1Obesity 1Melanoma 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Chronic Pain 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 6Radiotherapy 3Anastrozole 3Taxes 2Simvastatin 2Radiation 2Paclitaxel 2Neoadjuvant Therapy 2Letrozole 2Gene Expression Profiling 2Chemotherapy, Adjuvant 2Celecoxib 2telapristone acetate 1poly(I).poly(c12,U) 1oxybutynin 1liposomal doxorubicin 1exemestane 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Yoga 1Sugars 1Sentinel Lymph Node Biopsy 1Ranitidine 1Radiation Dose Hypofractionation 1Pharmacogenomic Testing 1Naltrexone 1Monitoring, Physiologic 1Mometasone Furoate 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Breast Carcinoma In Situ × Naltrexone × Clear all
NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡